These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6138947)

  • 1. Neurochemical and neuropharmacological indications for the involvement of GABA and glycine receptors in neuropsychiatric disorders.
    Lloyd KG; DeMontis G; Broekkamp CL; Thuret F; Worms P
    Adv Biochem Psychopharmacol; 1983; 37():137-48. PubMed ID: 6138947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of neurotransmitter actions (GABA, glycine, and convulsants).
    Davidoff RA
    Res Publ Assoc Res Nerv Ment Dis; 1983; 61():53-85. PubMed ID: 6133327
    [No Abstract]   [Full Text] [Related]  

  • 3. Glycine receptors in the human brain: characterization of 3H-strychnine binding and status in pathological conditions.
    Lloyd KG; De Montis G; Javoy-Agid F; Beaumont K; Lowenthal A; Constantinidis J; Agid Y
    Adv Biochem Psychopharmacol; 1983; 36():233-8. PubMed ID: 6305150
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycine receptors in the human substantia nigra as defined by [3H]strychnine binding.
    de Montis G; Beaumont K; Javoy-Agid F; Agid Y; Constandinidis J; Lowenthal A; Lloyd KG
    J Neurochem; 1982 Mar; 38(3):718-24. PubMed ID: 6276509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization and physiological properties of glycine and GABA receptors in cultures of rat CNS.
    Hösli L; Hösli E
    Adv Biochem Psychopharmacol; 1983; 37():35-46. PubMed ID: 6314764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications for the use of gamma-aminobutyric acid (GABA)-agonists in convulsant disorders.
    Lloyd KG; Munari C; Worms P; Bossi L; Morselli PL
    Prog Clin Biol Res; 1983; 124():285-97. PubMed ID: 6410408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABA and glycine receptors in CNS cultures: autoradiographic binding and electrophysiological studies.
    Hösli L; Hösli E; Andrès PF; Landolt H
    Adv Biochem Psychopharmacol; 1981; 29():437-43. PubMed ID: 6266226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.
    Nemeroff CB; Bissette G
    Prog Clin Biol Res; 1985; 192():333-41. PubMed ID: 2934745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.
    Chang L; Cloak CC; Ernst T
    J Clin Psychiatry; 2003; 64 Suppl 3():7-14. PubMed ID: 12662128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and therapeutic actions of GABA receptor agonists.
    Zivkovic B; Scatton B; Worms P; Lloyd KG; Bartholini G
    J Neural Transm Suppl; 1983; 18():319-26. PubMed ID: 6308150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
    Krystal JH; D'Souza DC; Petrakis IL; Belger A; Berman RM; Charney DS; Abi-Saab W; Madonick S
    Harv Rev Psychiatry; 1999; 7(3):125-43. PubMed ID: 10483932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycine and GABA(A) receptor subunits on Renshaw cells: relationship with presynaptic neurotransmitters and postsynaptic gephyrin clusters.
    Geiman EJ; Zheng W; Fritschy JM; Alvarez FJ
    J Comp Neurol; 2002 Mar; 444(3):275-89. PubMed ID: 11840480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra.
    Worms P; Depoortere H; Durand A; Morselli PL; Lloyd KG; Bartholini G
    J Pharmacol Exp Ther; 1982 Mar; 220(3):660-71. PubMed ID: 6278129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABA receptor binding and endogenous inhibitors in normal human brain and Huntington's disease.
    Olsen RW; Van Ness P; Napias C; Bergman M; Tourtellotte WW
    Adv Biochem Psychopharmacol; 1980; 21():451-60. PubMed ID: 6246754
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycinergic inhibition in thalamus revealed by synaptic receptor blockade.
    Ghavanini AA; Mathers DA; Puil E
    Neuropharmacology; 2005 Sep; 49(3):338-49. PubMed ID: 15993440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders.
    Chen L; Yung WH
    Sheng Li Xue Bao; 2004 Aug; 56(4):427-35. PubMed ID: 15322674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anesthetic-like modulation of a gamma-aminobutyric acid type A, strychnine-sensitive glycine, and N-methyl-d-aspartate receptors by coreleased neurotransmitters.
    Milutinovic PS; Yang L; Cantor RS; Eger EI; Sonner JM
    Anesth Analg; 2007 Aug; 105(2):386-92. PubMed ID: 17646495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
    Lloyd KG; Worms P
    Adv Biochem Psychopharmacol; 1981; 29():59-67. PubMed ID: 6114626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GABA(A) receptor subtypes as targets for neuropsychiatric drug development.
    Korpi ER; Sinkkonen ST
    Pharmacol Ther; 2006 Jan; 109(1-2):12-32. PubMed ID: 15996746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.